What Happened?
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 0.6% in the afternoon session after Canaccord Genuity Group raised its price target on the stock. The analyst firm lifted its target to $19.00 from $16.00 and kept a "buy" rating on the shares.
This move followed the company's recent quarterly earnings report from November 6th, where it posted results that were better than expected. The company reported earnings per share of ($0.22), beating the consensus estimate of ($0.27). Revenue for the quarter also came in higher at $149.00 million, ahead of the $142.50 million that analysts had forecast. Amid the positive news, the stock's price reached a new 52-week high, reflecting strong market performance.
After the initial pop the shares cooled down to $17.11, up 0.1% from previous close.
Is now the time to buy 10x Genomics? Access our full analysis report here.
What Is The Market Telling Us
10x Genomics’s shares are extremely volatile and have had 50 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 4 days ago when the stock gained 14.3% on the news that the company reported third-quarter financial results that beat Wall Street's expectations and provided an upbeat revenue forecast for the fourth quarter. For the third quarter, revenue came in at $149 million, exceeding the consensus estimate of $142.4 million. The company's loss per share of $0.22 was also narrower than the $0.28 loss analysts had predicted. Looking ahead, 10x Genomics projected fourth-quarter revenue to be in the range of $154 million to $158 million. The midpoint of this guidance surpassed analysts' forecasts, signaling confidence in its performance. Overall, the strong results and positive outlook appeared to drive investor optimism.
10x Genomics is up 20.6% since the beginning of the year, and at $17.11 per share, has set a new 52-week high. Investors who bought $1,000 worth of 10x Genomics’s shares 5 years ago would now be looking at an investment worth $125.24.
While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our full research report.